NCT02705482 - A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 30, 2016

Primary Completion Date

August 7, 2019

Study Completion Date

August 7, 2019

Conditions

Select Advanced Solid Tumors

Interventions

BIOLOGICAL

MEDI0562

Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.

BIOLOGICAL

Tremelimumab

Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.

BIOLOGICAL

Durvalumab

Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.

Trial Locations (12)

10032

Research Site, New York

28078

Research Site, Huntersville

37203

Research Site, Nashville

60611

Research Site, Chicago

63110

Research Site, St Louis

77030

Research Site, Houston

87106

Research Site, Albuquerque

90404

Research Site, Santa Monica

94805

Research Site, Villejuif

97213

Research Site, Portland

1066 CX

Research Site, Amsterdam

1081 HV

Research Site, Amsterdam